The US Food and Drug Administration (FDA) has granted priority review for Bristol Myers Squibb鈥檚 (BMS) Breyanzi (lisocabtagene maraleucel) to treat patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
The Prescription Drug User Fee Act (PDUFA) goal date for the therapy is now 14 March 2024.
BMS submitted a supplemental biologics licence application (sBLA) to the FDA for the expanded use of Breyanzi for the treatment of patients with CLL and SLL who have previously received a Bruton tyrosine kinase inhibitor (BTKi) and a B-cell lymphoma 2 inhibitor (BCL2i).
The application is based on results from the Phase I/II TRANSCEND CLL 004 study, which demonstrated clinical benefit with a CD19-directed CAR T cell therapy in patients with relapsed or refractory CLL after prior treatment with BTKi and BCL2i.
In May 2023, BMS received approval from the European Commission (EC) for Breyanzi to treat relapsed or refractory large B-cell lymphoma (LBCL) in adult patients.
Breyanzi is a type of CAR T cell therapy designed to treat specific types of lymphomas. The therapy is FDA-approved for the treatment of adult patients with various types of lymphomas and is specifically intended for patients who have not responded to initial chemo-immunotherapy treatment.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAccording to GlobalData, Breyanzi is forecast to generate $1.8bn by 2029.
GlobalData is the parent company of 色界吧 Technology.
BMS late clinical development cell therapy senior vice-president 鈥淐urrently, there is no standard of care for people living with relapsed or refractory CLL or SLL after treatment with BTKi-based and BCL2i-based regimens, leaving a critical unmet need for a treatment option that provides deep and lasting responses.鈥�
Cell & Gene Therapy coverage on 色界吧 Technology is supported by Cytiva. Editorial content is independently produced and follows the of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
